Login to Your Account

Top-Line Results By Year-End

Allos' PDX Yields Positive Interim Data in PTCL Trial

By Jennifer Boggs

Friday, May 16, 2008
As the industry prepared for the first deluge of American Society of Clinical Oncology (ASCO) data Thursday night, cancer drug company Allos Therapeutics Inc. managed to capture a little attention of its own early in the day by reporting promising interim data from its pivotal Phase II study of PDX (pralatrexate) in peripheral T-cell lymphoma (PTCL). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription